GNRH1 and Alzheimer disease: GnRH agonists and androgen receptor inhibitors were both associated with an increased risk of AD (RR, 1.79; 95% CI, 1.14–2.23; and RR, 1.23; 95% CI, 1.13–1.33; p <0.001), non‐AD dementia (RR, 1.57; 95% CI, 1.31–1.86; and RR, 1.25; 95% CI, 1.18–1.33; p <0.001).